Cargando…

Clinical Value of Mean Platelet Volume to Platelet Ratio (MPR) in Distinguishing Mass-Forming Chronic Pancreatitis and Pancreatic Cancer

Background: Correctly distinguishing mass-forming chronic pancreatitis (MFCP) from pancreatic cancer (PC) is of clinical significance to determine optimal therapy and improve the prognosis of patients. According to research, inflammation status in PC is different from that in MFCP. Mean platelet vol...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Han-Xuan, Li, Yu-Lin, Huang, Jin-Can, Ma, You-Wei, Lang, Ren, Lyu, Shao-Cheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10572152/
https://www.ncbi.nlm.nih.gov/pubmed/37835869
http://dx.doi.org/10.3390/diagnostics13193126
_version_ 1785120167751057408
author Wang, Han-Xuan
Li, Yu-Lin
Huang, Jin-Can
Ma, You-Wei
Lang, Ren
Lyu, Shao-Cheng
author_facet Wang, Han-Xuan
Li, Yu-Lin
Huang, Jin-Can
Ma, You-Wei
Lang, Ren
Lyu, Shao-Cheng
author_sort Wang, Han-Xuan
collection PubMed
description Background: Correctly distinguishing mass-forming chronic pancreatitis (MFCP) from pancreatic cancer (PC) is of clinical significance to determine optimal therapy and improve the prognosis of patients. According to research, inflammation status in PC is different from that in MFCP. Mean platelet volume/platelet ratio (MPR) is a platelet-related inflammation index which has been proven to be valuable in the diagnosis and prognosis of various malignant cancers due to the change in mean platelet volume and platelet count under abnormal inflammatory conditions caused by tumors. Thus, we conducted this study to investigate the clinical value of MPR in distinguishing MFCP from PC. Methods: We retrospectively analyzed the data of 422 patients who were suspected to have PC during imaging examination at our department from January 2012 to December 2021. Included patients were divided into the PC (n = 383) and MFCP groups (n = 39), according to their pathological diagnosis. Clinical data including MPR were compared within these two groups and the diagnostic value was explored using logistic regression. The ROC curve between MPR and PC occurrence was drawn and an optimal cut-off value was obtained. Propensity score matching was applied to match MFCP patients with PC patients according to their age and carbohydrate antigen 19-9 (CA19-9). Differences in MPR between groups were compared to verify our findings. Results: The area under the ROC curve between MPR and PC occurrence was 0.728 (95%CI: 0.652–0.805) and the optimal cut-off value was 0.045 with a 69.2% sensitivity and 68.0% accuracy. For all the included patients, MPRs in the MFCP and PC groups were 0.04 (0.04, 0.06) and 0.06 (0.04, 0.07), respectively (p = 0.005). In patients with matching propensity scores, MPRs in the MFCP and PC groups were 0.04 (0.03, 0.06) and 0.06 (0.05, 0.08), respectively (p = 0.005). Multiple logistic regression in all included patients and matched patients confirmed MPR and CA19-9 as independent risk markers in distinguishing PC. Combining CA19-9 with MPR can increase the sensitivity and accuracy in diagnosing PC to 93.2% and 89.5%, respectively. Conclusion: MPR in PC patients is significantly higher than that in MFCP patients and may be adopted as a potential indicator to distinguish MFCP and PC. Its differential diagnosis capacity can be improved if combined with CA19-9.
format Online
Article
Text
id pubmed-10572152
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-105721522023-10-14 Clinical Value of Mean Platelet Volume to Platelet Ratio (MPR) in Distinguishing Mass-Forming Chronic Pancreatitis and Pancreatic Cancer Wang, Han-Xuan Li, Yu-Lin Huang, Jin-Can Ma, You-Wei Lang, Ren Lyu, Shao-Cheng Diagnostics (Basel) Article Background: Correctly distinguishing mass-forming chronic pancreatitis (MFCP) from pancreatic cancer (PC) is of clinical significance to determine optimal therapy and improve the prognosis of patients. According to research, inflammation status in PC is different from that in MFCP. Mean platelet volume/platelet ratio (MPR) is a platelet-related inflammation index which has been proven to be valuable in the diagnosis and prognosis of various malignant cancers due to the change in mean platelet volume and platelet count under abnormal inflammatory conditions caused by tumors. Thus, we conducted this study to investigate the clinical value of MPR in distinguishing MFCP from PC. Methods: We retrospectively analyzed the data of 422 patients who were suspected to have PC during imaging examination at our department from January 2012 to December 2021. Included patients were divided into the PC (n = 383) and MFCP groups (n = 39), according to their pathological diagnosis. Clinical data including MPR were compared within these two groups and the diagnostic value was explored using logistic regression. The ROC curve between MPR and PC occurrence was drawn and an optimal cut-off value was obtained. Propensity score matching was applied to match MFCP patients with PC patients according to their age and carbohydrate antigen 19-9 (CA19-9). Differences in MPR between groups were compared to verify our findings. Results: The area under the ROC curve between MPR and PC occurrence was 0.728 (95%CI: 0.652–0.805) and the optimal cut-off value was 0.045 with a 69.2% sensitivity and 68.0% accuracy. For all the included patients, MPRs in the MFCP and PC groups were 0.04 (0.04, 0.06) and 0.06 (0.04, 0.07), respectively (p = 0.005). In patients with matching propensity scores, MPRs in the MFCP and PC groups were 0.04 (0.03, 0.06) and 0.06 (0.05, 0.08), respectively (p = 0.005). Multiple logistic regression in all included patients and matched patients confirmed MPR and CA19-9 as independent risk markers in distinguishing PC. Combining CA19-9 with MPR can increase the sensitivity and accuracy in diagnosing PC to 93.2% and 89.5%, respectively. Conclusion: MPR in PC patients is significantly higher than that in MFCP patients and may be adopted as a potential indicator to distinguish MFCP and PC. Its differential diagnosis capacity can be improved if combined with CA19-9. MDPI 2023-10-04 /pmc/articles/PMC10572152/ /pubmed/37835869 http://dx.doi.org/10.3390/diagnostics13193126 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Wang, Han-Xuan
Li, Yu-Lin
Huang, Jin-Can
Ma, You-Wei
Lang, Ren
Lyu, Shao-Cheng
Clinical Value of Mean Platelet Volume to Platelet Ratio (MPR) in Distinguishing Mass-Forming Chronic Pancreatitis and Pancreatic Cancer
title Clinical Value of Mean Platelet Volume to Platelet Ratio (MPR) in Distinguishing Mass-Forming Chronic Pancreatitis and Pancreatic Cancer
title_full Clinical Value of Mean Platelet Volume to Platelet Ratio (MPR) in Distinguishing Mass-Forming Chronic Pancreatitis and Pancreatic Cancer
title_fullStr Clinical Value of Mean Platelet Volume to Platelet Ratio (MPR) in Distinguishing Mass-Forming Chronic Pancreatitis and Pancreatic Cancer
title_full_unstemmed Clinical Value of Mean Platelet Volume to Platelet Ratio (MPR) in Distinguishing Mass-Forming Chronic Pancreatitis and Pancreatic Cancer
title_short Clinical Value of Mean Platelet Volume to Platelet Ratio (MPR) in Distinguishing Mass-Forming Chronic Pancreatitis and Pancreatic Cancer
title_sort clinical value of mean platelet volume to platelet ratio (mpr) in distinguishing mass-forming chronic pancreatitis and pancreatic cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10572152/
https://www.ncbi.nlm.nih.gov/pubmed/37835869
http://dx.doi.org/10.3390/diagnostics13193126
work_keys_str_mv AT wanghanxuan clinicalvalueofmeanplateletvolumetoplateletratiomprindistinguishingmassformingchronicpancreatitisandpancreaticcancer
AT liyulin clinicalvalueofmeanplateletvolumetoplateletratiomprindistinguishingmassformingchronicpancreatitisandpancreaticcancer
AT huangjincan clinicalvalueofmeanplateletvolumetoplateletratiomprindistinguishingmassformingchronicpancreatitisandpancreaticcancer
AT mayouwei clinicalvalueofmeanplateletvolumetoplateletratiomprindistinguishingmassformingchronicpancreatitisandpancreaticcancer
AT langren clinicalvalueofmeanplateletvolumetoplateletratiomprindistinguishingmassformingchronicpancreatitisandpancreaticcancer
AT lyushaocheng clinicalvalueofmeanplateletvolumetoplateletratiomprindistinguishingmassformingchronicpancreatitisandpancreaticcancer